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Collection of exhaled breath condensate (EBC) is a non-invasive means of sampling the airway-
lining fluid of the lungs. EBC contains numerous measurable mediators, whose analysis could
change the management of patients with certain pulmonary diseases.
While initially popularized in investigations involving spontaneously breathing patients, an
increasing number of studies have been performed using EBC in association with mechanical
ventilation. Collection of EBC in mechanically ventilated patients follows basic principles of
condensation, but is influenced by multiple factors. Effective collection requires selection
of a collection device, adequate minute ventilation, low cooling temperatures, and sampling
times of greater than 10 min. Condensate can be contaminated by saliva, which needs to be
filtered. Dilution of samples occurs secondary to distilled water in vapors and humidification
in the ventilator circuit. Dilution factors may need to be employed when investigating non-
volatile biomarkers. Storage and analysis should occur promptly at 70 C to 80 C to prevent
rapid degradation of samples.
The purpose of this review is to examine and describe methodologies and problems of EBC
collection in mechanically ventilated patients. A straightforward and safe framework has been
established to investigate disease processes in this population, yet technical aspects of EBC
collection still exist that prevent clinical practicality of this technology. These include a lack
of standardization of procedure and analysis of biomarkers, and of normal reference ranges for
mediators in healthy individuals. Once these procedural aspects have been addressed, EBC
could serve as a non-invasive alternative to invasive evaluation of lungs in mechanically venti-
lated patients.
ª 2012 Elsevier Ltd. All rights reserved.327 2477 (mobile); fax: þ1 708 327 2813, þ1 708 327 2438 (lab).
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Non-invasive methods of examining inflammatory markers
of respiratory disease have been an area of interest in
pulmonary research over the past few decades. EBC
collection is a relatively new technique by which pulmonary
specimens are obtained. EBC is the liquid form of exhaled
gases and vapors collected in a portable condenser. It is
derived from aerosolized non-volatile particles contained in
fluid lining the airway, volatile water-soluble molecules
that have been aerosolized and condensed, and distilled
water from moisture within the airway itself.1 EBC can
safely be collected from both actively participating
patients breathing on their own, or during mechanical
ventilation by placing a collection device in-line with the
expiratory circuit of the ventilator.2,3
Collection of EBC was first described in 1980 in the
former Soviet Union, but has recently been revisited as
a non-invasive means of analyzing properties of the lung.4,5
Investigations of EBC have been performed in a multitude
of inflammatory conditions and connective tissue disorders
including chronic obstructive pulmonary disease (COPD),
acute lung injury (ALI), adult respiratory distress syndrome
(ARDS), asthma, pneumonia, sarcoidosis and many more.
These investigations have revealed identifiable patterns of
change in an array of biomarkers that are measurable in
EBC.6e10 Biomarkers include, but are not limited to nitric
oxide (NO), eicosanoids such as leukotrienes, prostanoids
and isoprostanes, products of lipid peroxidation, hydrogen
peroxide (H2O2), and inflammatory proteins and cytokines.
By examining the inflammatory biomarker profiles of
specific disease processes, EBC has the potential to be
helpful as a prognosticator of outcomes and may help guide
treatment.
The anatomy and physiology of the pulmonary system
make it difficult to obtain samples from deep within the
lungs. Current methods of evaluating pathology of the lung
include less invasive methods such as pulmonary function
testing, imaging techniques and sputum cultures, as well as
more invasive methods such as bronchoalveolar lavage
(BAL), bronchoscopy, and tissue biopsy. One of the major
problems with the more invasive methods is that they
cannot be performed frequently secondary to risksassociated with procedures. EBC is a means of monitoring
biomarkers in the airways of diseased or injured patients
that is quick, repeatable, and is minimal risk to the patient.
The non-invasive nature of EBC is a significant advantage
from the standpoint of patient safety making it a tech-
nology worth pursuing.
Mechanically ventilated patients, generally speaking,
are at a greater severity of illness and therefore would
benefit from less invasive means of testing. If results are
found to be reproducible, EBC could replace more invasive
methods of sampling airway-lining fluids. To date, signifi-
cant biomarkers identified by EBC in mechanically venti-
lated patients focus mostly on airway inflammation. Studies
have successfully monitored pH in mechanically ventilated
patients, suggesting possible correlation with pro-
inflammatory cytokines and overall inflammation.2,11 Mye-
loperoxidase (MPO) and 8-isoprostane levels have been
measured in multiple studies and were elevated in one
looking at mechanically ventilated patients with severe
pulmonary infection, suggesting inflammation due to
increased reactive oxygen species (ROS).3,12e15 Studies
examining intubated patients with inflammatory lung
diseases (ALI/ARDS) and COPD, found higher levels of all
investigated cytokines (IL-1b, IL-6, IL-8, IL-10, TNFa, IL-
12p70) in comparison to healthy smoking and non-smoking
volunteers.9,16 Evidence of the clinical potential of EBC
has been demonstrated in this subset of patients, but
remains a work in progress with potential biomarkers still
being established. The purpose of this review is to examine
and describe the methodology and problems of EBC
collection as they pertain to the mechanically ventilated
patient.EBC collection in mechanical ventilation
Collection of EBC is straightforward and is most commonly
described in studies involving active participants breathing
into a portable device,17 although a smaller number of
studies have successfully incorporated this technology into
mechanical ventilator circuits. There is currently no stan-
dardization to the use of EBC devices in a clinical setting,
nor have reference ranges been established for specific
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Respiratory Society (ATS/ERS) created a task force on EBC
to help determine guidelines in its use. These recommen-
dations serve as a guide for future studies (Table 1).8
The general principle of EBC is no different than
condensation of other gases. Exhaled gas is blown into the
collection device and cools as heat is transferred to the
cold chamber walls. Once the air reaches a temperature
below its dew point, the aerosolized particles begin to
condense and form droplets. The droplets are then
collected in a container, which is stored or sent for analysis.
Technical considerations when performing EBC collec-
tion in mechanically ventilated patients include choice of
collection device, technique of collection, storage condi-
tions of condensate and methods of analysis of biomarkers.
These elements have been described in existing studies
using EBC in mechanical ventilation (Table 2) and are
summarized in the following sections.Table 1 ATS/ERC task force recommendation summary as pert
Standardization issue Recommendation
General Standardize sampling, storage and
e Sampling device Delineate device used. If commer
and precise modifications. If custo
used and provide sufficient diagra
employed equipment.
e Sampling temperature Specify the collection temperatur
e Duration of collection Duration should be recorded.
e Contamination Test all materials that contact EB
are in place.
e Biomarker Storage Unless proven unnecessary, store
available.
Stability in storage Data should be presented regardin
publications addressing the stabili
e Stabilization of marker When possible, this should be per
e Assay In all cases, use assays proven to
for the marker of interest in EBC.
Timing Assays should be performed as soo
marker or contamination with exo
e Validation in EBC Assay systems should be tested fo
e Immunoassays Assure that nonspecific binding is
appropriate controls are performe
e Nitrogen Oxide Report precisely what was measur
oxide (NO) without providing a de
Clearly note the NO that are inclu
e pH Report if de-aerated (or gas-stand
de-aerated, note the timing of the
e Spectrophotometry
and other assays
Assure sufficient controls, and tha
e Dilution issues Consider volatile and non-volatile
Present finding of non-volatile cau
factor or relevant ratio.
e New markers Skeptically consider the specificity
Determine the possibility of conta
in storage.
EBC: exhaled breath condensate. NO: Nitrogen Oxide. Strength of Reco
Force experts; 4) Compelling data or when data are unnecessary, stron
2) Little or no data, majority opinion; 1) No published data, opinionsCollection devices
Studies looking at EBC in mechanically ventilated patients
describe use of custom as well as commercially available
collection devices. Custom EBC collection devices are
constructed using tubing, often described as Teflon, glass,
or another material, or glass chambers in line with the
expiratory limb of the ventilator circuit. A long portion of
the tubing is submerged in an ice bath or other cooling
mechanism, with a collection tube or container at the distal
end18e24 (Fig. 1).
Recent studies have more frequently used commercial
devices to collect EBC when working with mechanically
ventilated patients. These devices include R-Tube (Respi-
ratory Research, USA), ECoScreen (FILT Lung and Chest
Diagnostics Ltd, Germany), TURBO-DECCS (Medivac, Italy),
and ANACON (Biostec, Valencia, Spain)5 (Table 3).ains to mechanical ventilation.
Strength of
recommendation
assay type within an individual study. 3
cial, note the name and manufacturer
m, clearly detail the device, materials
ms to allow understanding of the
5
e or range. 4
2
C and assure adequate controls 4
samples in the coldest temperature 3
g marker stability in EBC, or previous
ty of the specific marker referenced.
4
formed. 2
be sufficiently sensitive and specific 5
n as possible to avoid loss of
genous marker.
4
r utility in EBC. 5
identified and minimized, and that
d in all cases.
4
ed. Do not use the term nitrogen
finition for that term in the manuscript.
ded in the assay used.
4
ardized) and by what means. If not
measurement after collection.
5
t the assay is in range. 4
constituents of EBC differently.
tiously in the absence of a dilution
4
and sensitivity of the assay.
mination. Determine stability
3
mmendations: 5) Unequivocal data and/or unanimity among Task
g consensus; 3) Little data, or data unnecessary, with consensus;
of panel.
Table 2 Summary of EBC collection methods involving mechanical ventilation.
Device used Humidification Collection time Collection
temp
Storage
temp
Biomarker Authors
R-Tube Disconnected 20 min 20 C 80 C pH, IL-10, IL-1b, IL-6,
IL-8, IL 12p70, TNFa
Korovesi I et al., 2011
EcoScreen/
R-Tube
Connected 10e20 min e14 to 7 C 70 C MPO, HNL Davidsson A et al., 2010
ECoScreen Disconnected Time needed
to collect 2 ml
10 C 70 C pH, nitrite/nitrate,
8-isoprostane
Roca O et al., 2010
ECoScreen Disconnected 25e45 min 20 C 70 C pH, nitrite/nitrate,
8-isoprostane, LTB4
Roca O et al., 2008
ECoScreen Connected 30 min NR NR IL-6, IL-8, Protein Gessner C et al., 2007
Custom NR 30 min 4 C NR sTREM-1 Horonenko G et al., 2007
ECoScreen Both 30 min 10 C 80 C 8-isoprostane Mu¨ller WG et al., 2006
Anacon Disconnected 15 min or
greater
< 10 C 80 C nitrite/nitrate,
8-isoprostane, MPO
Romero PV et al., 2006
ECoScreen Connected 20 min 10 C NR IL-1b, IL-6, IL-8, IL-10,
TNFa, and IL-12p70
Sack U et al., 2006
R-Tube Connected 10 min 0 C N/A pH Walsh BK et al., 2006
Custom NR 30e60 min NR 80 C H2O2 Bruhn A et al., 2005
ECoScreen Connected 20 min NR NR IL-1b, IL-6, IL-8, IL-10,
TNFa, and IL-12p70
Gessner C et al., 2005
R-Tube Disconnected 15 min 20 C 70 C pH, H2O2, LTB4, MPO,
8-Isoprostane
Moloney ED et al., 2004
ECoScreen Connected 30 min 10 C NR pH, ammonia, lactate,
pCO2, HCO3
, IL-6, IL-8
Gessner C et al., 2003
ECoScreen Connected 30 min 10 C 4 C Nitrate, IL-6, IL-8 Gessner C et al., 2003
Custom NR 20e30 min 5 C 70 C H2O2 Heard SO et al., 1999
Custom Disconnected 30e60 min NR 70 C 8-isoprostane Carpenter CT et al., 1998
Custom 15e30 min NR NR pCO2, pO2 Von Pohle WR et al., 1992
Custom NR 20 min 5 to 0 C N/A H2O2 Sznajder JI et al., 1989
Custom NR 5 min NR 70 C H2O2 Baldwin SR et al., 1986
Biomarker: LTB4 - Leukotriene B4, MPO - Myeloperoxidase, HNL - Human Neutrophil Lipocalin, H2O2 - Hydrogen Peroxide, TNFa - Tumor
Necrosis Factor alpha, sTREM-1 - Soluble Triggering Receptor Expressed on Myeloid Cell-1, pCO2 - Partial pressure of CO2, pO2 - Partial
pressure of O2. NR - Not Recorded.
604 S.R. Carter et al.R-Tube is a handheld, single-use disposable tube that
can be attached to the expiratory circuit of a mechanical
ventilator in-line with the endotracheal tube and venti-
lator tubing. Modification by removal of the expiratoryFigure 1 Schematic for custom EBC collection device: Tubing
is submerged in ice bath with a collection chamber at the distal
end. Tubing is attached to the expiratory circuit of the vent.
Figure modified from Mutlu et al 2001.46valve to decrease airway resistance has been described for
this application2,25,26 (Fig. 2). The R-Tube is placed level
on its side to prevent collected fluid from spilling back into
the vent tubing. Temperature is reduced with an
aluminum-cooling sleeve, which slides around the
condenser tube. The circuit will need to be interrupted
briefly in order to get the cooling sleeve around the
attached tube. Typically the sleeve is cooled to 70 to
80 C according to studies using this device.25e29 The
temperature at which EBC is collected gradually increases
secondary to ambient temperature, including room
temperature and that of the exhaled vapors, therefore
limiting the amount of time for effective collection. To
circumvent this issue, maintenance of a set condensing
temperature has been described with an optional contin-
uous cooling unit.5 Once collection is finished, the R-tube
is disconnected, capped on both ends with rubber caps
preventing condensate on the walls of the Teflon tube from
spilling, and placed on ice. The plunger valve, which was
previously removed, will need to be reinserted for
collection of the flud and processing.
In contrast to the R-Tube, ECoScreen is a larger portable
collection device that has additional features including an
Table 3 EBC collection devices.
EBC collection
device
Manufacturer Ventilator use Cooling method Temperature
control
Lowest
temperature
Advantages Disadvantages
Biostec, Valencia,
Spain
Specifically
designed for
mechanical
ventilation
Built in cooling
unit
Yes 10 C Built in cooling unit allows for
temperature control. Collection
chamber connected to device,
allowing for easy condensate
collection. Specifically designed
for use with a mechanical
ventilator.
It is difficult to assess this
device due to a lack of
supporting literature.
ECoScreenI Viasys, USA,
Europe
Yes, adaptable
to ventilor
Built in cooling
unit
No 20 C Well described in literature.
Built in cooling unit allows for
stable temperature.
Expensive and more
cumbersome device. Size
makes it more difficult to
transport to an ICU.
Requires cleaning in
between uses. Additional
conduits required for use
in mechanical ventilation.
Doesn’t allow for
temperature adjustment
ECoScreenII Viasys, USA,
Europe
Yes, adaptable
to ventilor
Built in cooling
unit
Yes 20 C More extensive use in European
centers. Built in cooling unit
allows for adjustable
temperature control. When
compared to its predecessor,
it was found to collect more
sample with higher
concentration of biomarker.
Expensive and more
cumbersome device. Size
makes it more difficult
to transport to an ICU.
Requires cleaning in
between uses. Additional
conduits required for use
in mechanical ventilation.
R-Tube Respiratory
Research, USA
Yes, adaptable
to ventilor
Metal cooling
sleeve stored
in freezer
No Dependent
on cooling
sleeve
Inexpensive and easily
portable. Disposable device,
therefore no cleaning
necessary. Well described
in the literature.
Adaptation to the
mechanical ventilator
requires disassembling
the device. Ambient
temperature affects
collection.
TURBO-DECCS Medivac, Italy Yes, adaptable
to ventilor
Built in cooling
unit
No 10 C Multiple units can be
placed in the circuit for
simultaneous sample
collection. Built in
cooling unit with
adjustable temperature.
Medium sized. Disposable
parts allow for easier
cleaning.
Expensive. Additional
conduits required for
use in the mechanical
ventilator. Limited
use in literature.
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Figure 2 Schematic for R-tube collection device: The device is connected to the expiratory circuit of a mechanical ventilator.
Expiratory valve may be removed to adapt to the vent. Figure modified from Moloney et al. 2004.12
606 S.R. Carter et al.optional spirometer, separate collection chambers allowing
for fractioning of condensate and sampling from different
portions of the airway, saliva trap for removal of contami-
nant, and an electrical cooling system that allows for main-
tenance of the condenser temperature. A drawback to the
ECoScreenI device was that the investigator could not alter
the temperature of the cooling system due to a set temper-
ature. Maintenance of the device is also more time
consuming because the device requires cleaning between
uses. In order to adapt the ECoScreen for use inmechanically
ventilated patients, additional conduits were needed to
attach the device to the expiratory circuit3,11,13,14,16,29
(Fig. 3). The ECoScreenI device is no longer being manufac-
tured. Its successor, the ECoScreenII, can be adapted for
mechanical ventilation, although this is less well defined in
the literature (FILT, Lung and Chest Diagnostics, LTD, Ger-
many). The ECoScreenII device includes an adjustable ther-
moelectrically cooled condenser, reaching temperatures as
low as 20 C. A comparison study between the ECoScreenI
and II devices showed that the ECoScreenII collected larger
sample volumes and greater concentrations of biomarker for
analysis. Samples were also found to be more acidic.30Figure 3 Schematic for ECoScreen and TURBO-DECCS device
Figure modified from Mu¨ller et al 2006.3TURBO-DECCS is another portable collection device
that has an electrical cooling system, ranging from
10e35 C. It differs from the ECoScreenI in that it has an
adjustable temperature control for cooling the condenser
unit. It also has disposable connectors for sample collec-
tion, making cleaning between uses easier. Use of the
TURBO-DECCS in the literature is limited, but the manu-
facturer has designed specific adaptors for mechanical
ventilators, which must be purchased separately, as well
as connectors to place multiple units in line with a single
vent to collect multiple specimens simultaneously (Medi-
vac, Italy). Assembly of the TURBO-DECCS to the venti-
lator is not dissimilar to the ECoScreen setup with the
device attached to the expiratory limb of the ventilator
(Fig. 3).
ANACON is a condensing unit that is inserted directly into
the expiratory branch of the ventilator circuit via adaptors
that are part of the device (Fig. 4). It uses a thermoelectric
pump to generate low temperatures that reach below
10 C, which can be adjusted by the investigator.15
Unfortunately, descriptions of this device in practice are
limited.s: Temperature regulated condenser with in-line adaptor.
Figure 4 Schematic for ANACON collection device: Temperature regulated condenser inserted directly into vent circuit.
Figure modified from Romero et al. 2006.15
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Once the collection device is attached to the ventilator,
multiple factors will influence the amount and quality of
condensate collected. Such factors include: minute venti-
lation, duration and temperature at which the specimen is
collected, the presence of contaminants such as saliva,31
and diluting elements including built-in humidifiers in the
ventilation circuit.3,8
A study byGessner et al. focused specifically on the role of
pulmonary function including minute ventilation and the
effects on EBC volume.32 They compared EBC collection in
healthy volunteers and COPD patients, looking at the effects
that lung function may have on efficiency. Their results
showed that none of the pulmonary function parameters
measured (total lung capacity, vital capacity, residual
volume, FEV1, and airway resistance), or patient related
variables such as height or weight, correlated with EBC
volume collected. EBC collection in both groups was
comparable and found to be strongly dependent on minute
ventilation, with larger total respired volumes resulting in
greater condensate yield. The trend between minute venti-
lation was initially examined in an animal model using
calves,33 but has been revisited in humans. A positive
correlation between minute ventilation and condensate
volume was shown in a study involving 30 healthy patients
voluntarily breathing into the ECoScreen device at different
set rates. Interestingly, these investigators found no dilution
effect on EBCprotein, nitrite concentrations, or pH.34 Minute
ventilation is not routinely documented in existing studies
involving mechanically ventilated patients. Given the trend
towards lower tidal volumes in mechanical ventilation, EBC
collection volumes may be lower due to decreased minute
ventilation, but this has yet to be examined.
Temperature of the condenser during collection varies
depending on the cooling systems of the devices used.
Condensation can be achieved around 0 C, though a range
of temperatures has been described. Low collection
temperatures have been documented at 20 C,12,14,25 andthe highest documented collection temperature in studies
with mechanically ventilated patients was 10 C.11,16,35
Importantly, temperature at which EBC is performed has
been shown to impact collection volumes. McCafferty et al.
monitored airway temperatures in 2005, showing that less
humidity in patient airways yielded less collected conden-
sate.34 Moreover, Goldoni et al showed a trend towards
higher condensate volume yield at lower condenser
temperatures in 2005.26 These findings are consistent with
principles of condensation, with moisture being more
abundant at higher airway temperatures, and more
condensation forming in a colder collection device. The
ambient temperature was also found to have an impact on
pH value of EBC, with higher pH values at higher temper-
atures.36 To our knowledge no formal evaluation of patient
airway temperature on EBC collection has been performed,
but one would expect patient temperature to affect
volume and pH of samples collected. The ATS/ERS task
force on EBC recommends routine documentation of
collection temperatures of condensate.
Collection times reflected in the literature are approxi-
mately 5e15 min for every 1 ml of EBC.1 Most studies report
1 mle3 ml of collected sample with collection times on
mechanical ventilators ranging from 5 min to 1 h.18,19
Collection volume is dependent on duration of collection,
but dilution of biomarkers becomes an issue as more of the
distilled water component collects. Longer EBC collection
periods have been documented with lyophilization of the
condensate to concentrate biomarkers of interest.16
Current ATS/ERS recommendations include documentation
of collection times as well as at least 10 min of collection
time for most mediators.
Contamination of EBC specimens is mostly from the oral
and retropharyngeal portions of the airway, with saliva being
the significant source. Depending on the device used during
EBC collection, there can be substantial gross or microscopic
contamination by saliva.31 While some devices have built-in
saliva traps to prevent contamination (ECoScreen, TURBO-
DECCS), theoretically, salivary contamination should be
608 S.R. Carter et al.less of an issue in mechanically ventilated patients. The
endotracheal tube cuff, when properly inflated, should
prevent saliva from draining into the lower airway. Oral
intake of foods, liquids and medications should not be an
issue in mechanically ventilated patient for the same
reason, although these factors have not been thoroughly
examined in studies with EBC in the general population. In
mechanically ventilated patients, the assembly with the
collection device is sampling the lower airways, excluding
the airway above the level of the endotracheal tube. Based
on experience of previous studies, some believe that moni-
toring for salivary contamination by condensate amylase
measurement is unnecessary, but efforts to prevent salivary
contamination should still be made.8
Dilution of samples is one of the most significant prob-
lems when evaluating biomarkers through EBC collection.
While most compounds collected from EBC are detectable
in concentrations that are measurable by existing assays
(leukotriene B4, 8-isoprostane, ammonia, hydrogen ion,
and nitrate), some compounds are identified at concen-
trations close to their lower limits of detection.1 With
additional dilution, these biomarkers may become unde-
tectable. Dilution can come from multiple sources,
including excess moisture in airway vapors, mucous formed
from the airway epithelium, and in the case of mechanical
ventilation, there is evidence that heated humidification
systems may dilute EBC samples.3,8 Along these lines,
studies collecting EBC from mechanically ventilated
patients have been performed with humidification con-
nected2,9,11,16,29,37 and disconnected.12e16,18 Mu¨ller et al.
studied the effects of humidification on EBC in mechan-
ically ventilated children using 8-isoprostane as
a biomarker. They found that levels of 8-isoprostane were
not detectable in humidified EBC samples or in the sterile
water used for humidification. While evidence suggests
dilution, there are no clear recommendations for or against
disconnecting humidification circuits during EBC collection
in mechanically ventilated patients at this time.
Dilution factors have been used in order to normalize
concentrations of biomarkers collected in EBC. This is
justified by the assumption that the constituents of EBC
(solutes and water vapors) are variable in collections,
therefore substances that have known serum concentrations
that diffuse through cell membranes and are not produced in
the alveoli can be measured in EBC and used to estimate
actual concentration of the diluted biomarkers. Dilution
factors in the literature have included exhaled volume,38
exhaled ions such as sodium and chloride,39e41 urea,39,42
protein concentration32 and conductance of lyophilized
samples.39 Despite the inherent dilemma of these dilution
factors, it has not yet been convincingly demonstrated that
normalization results in better reproducibility of biomarker
measurement in EBC.8 The ATS/ERS task force currently
recommends the use of a dilution factor when examining
non-volatiles found in the airway-lining fluid, whereas no
dilution factor is needed for volatile biomarkers.
Other factors that could potentially influence EBC
collection include patient related factors such as diseases
limiting pulmonary function. For example, in patients with
ARDS, lower tidal volume ventilation is routinely practiced,
which would result in lower EBC collection volume. Events
such as mucous plugging could potentially limit the area ofthe lung sampled by EBC due to blocked airway passages as
well as decrease the amount of sample collected.
Storage of samples
Once collected, depending on the biomarker of interest,
the specimen can either be processed immediately (H2O2,
L-Lactate, pH) or stored in a freezer for delayed processing.
Freezing temperatures of 70 to 80 C are used for storing
condensate in order to maintain stability of other
biomarkers. Care must be taken to process samples as soon
as possible or place in storage. Ambient air can interact
with EBC samples, especially if they are left at room
temperature, potentially changing composition of
biomarkers. It is also advised to avoid multiple fros-
tingedefrosting cycles secondary to subsequent degrada-
tion of the mediators.8 The ATS/ERS also suggest that
addition of a marker-free protein to EBC samples may
increase or lessen the loss of unstable markers, although
this recommendation is not absolute.
Analysis of EBC samples
Biomarkers that have been investigated in exhaled breath
include non-volatile compounds that are mostly derived
from the airway-lining fluid as well as water-soluble volatile
compounds, which are more readily assayed.1 The
concentration of some volatile and non-volatile substances
measured in EBC varies considerably, making it difficult to
validate individual biomarkers. While dilution of biomarkers
is one factor affecting consistent measurement, another is
the limitation of assays used to detect mediators.27 The
inability of an assay to detect low levels of certain medi-
ators contributes significantly to variability seen. Most
assay systems are not designed for use with EBC, which is
a very dilute fluid that is protein and buffer poor; there-
fore, it is important that assay systems be tested for utility
in EBC prior to standard use.8
Biomarkers that have been studied and reported in
patients on mechanical ventilators are similar to those in
spontaneously breathing individuals. These include
H2O2,
12,19,20,22,23 NO,11,13e15 leukotrienes,12,13 8-iso-
prostane,3,12e15,18 pH,2,11e14,25 ammonia,25 cyto-
kines,9,11,16,25,29 protein,29 MPO,12,15,37 and other specific
receptors. Continuous pH monitoring has successfully been
performed in mechanically ventilated patients.2
Currently there is no standardization of collection or
processing EBC. Some studies have stressed the importance
of using dilution factors for more volatile compounds
collected, but this is not done consistently. At the same
time, there are no reference values of normal levels of
biomarkers in the general population. Attempts have been
made at establishing reference values through reviewing
the results of biomarkers in existing studies.43,44 Small
subject numbers as well as a lack of standard procedure
limits these data. Other methods of standardization, such
as comparison of EBC to BAL fluid have been attempted.9,45
Studies examining levels of inflammatory cytokines in BAL
fluid and EBC in patients with severe COPD showed no
significant correlation between biomarkers in the two fluid
types.9 Possible reasons for observed differences include
Exhaled breath condensate collection in the mechanically ventilated patient 609the dilute nature of EBC as well as the fact that it is
collected from the entire lung as opposed to BAL, where
a specific area within the lung is sampled either blindly or
under direct visualization.
A significant issue facing EBC use in a clinical setting is its
lack of standardization. Multiple collection devices are
available and individual investigators decide upon device as
well as protocol in terms of specimen collection. Variation in
collection times, temperatures, and conditions (such as
ventilator settings and whether or not a humidification
circuit is connected) is widespread among existing studies.
Until collection methods have been standardized, it will be
difficult to reliably compare information between different
investigations.
Methods for analysis and interpretation of relevant
biomarkers also need to be standardized. There remains far
too much variability in analysis of biomarkers, preventing
the comparison of information between studies. Until
a reliable range of reference values has been established in
normal individuals, increases or decreases in values of
particular biomarkers relative to their controls will provide
more information than their absolute values. As previously
mentioned, the use of existing assays may not be reliable
given the dilute nature of EBC.
The ideal conditions for collecting specific biomarkers
vary depending on the nature of the substance, volatile
versus non-volatile, collection temperature, and duration
of collection. Optimum assay systems also differ substan-
tially for the markers measured in EBC. The ATS/ERS task
force states it is not scientifically appropriate to stan-
dardize a broad collection technique for biomarkers. In
doing so, it could greatly limit innovation in a relatively new
technique. Optimization for one marker will potentially
make another marker’s collection or assay suboptimal.
Disagreement will exist between investigators as to normal
levels of a biomarker until all aspects of an EBC sampling
and assay procedure are standardized, but standardization
will need to be marker specific.8Safety
The safety of EBC has been illustrated through repeated use
without significant adverse events. Over 10,000 individual
collections have been performed using different devices in
laboratories all over the world and no adverse events have
been reported.8 Suggested risks associated with mechanical
ventilation include ice formation in the tubing resulting in
limited expiratory flow,46 possible accidental extubation
with manipulation of the endotracheal tube, infection and
the potential for seriously ill patients to become unstable
during specimen collection.3
Limitation of expiratory flow secondary to ice formation
is described in the setting of collection using very low
temperatures with liquid nitrogen or dry ice, and is more
likely with prolonged collection times. If overlooked, this
could lead to hyperinflation of the lungs,46 a potentially
serious problem. Constant monitoring while performing
EBC, as well as shorter collection times at low tempera-
tures should prevent this complication.
With manipulation of the endotracheal tube (ETT), there
is always a risk of accidental extubation. By connecting theETT to a collection device, the patient’s range of head
motion will be restricted, and sudden movements could
potentially dislodge the tube. The ETT should be safely
secured and the position at the patient’s lip should be
noted prior to manipulation. Collection of EBC on
mechanically ventilated patients should not be performed
without available medical professionals such as physicians,
nurses and respiratory therapists to address any potential
problems. When connecting and disconnecting the device,
careful attention and optimal positioning are important in
minimizing risk.3
The introduction of infection by manipulation of the ETT
is also a concern when connecting or disconnecting
collection devices. There is no clear association between
ETT handling technique and pneumonia in the literature,47
but sterile technique should be used regardless during EBC
collection. Disposable devices should be used where
possible. If the collection device is not disposable then
proper sterilization of the device should be performed in
between uses. In the event that a patient is too unstable for
EBC collection, the procedure should be aborted. While the
potential for adverse events during EBC collection exists,
serious adverse events have not been reported in sponta-
neously breathing or mechanically ventilated patients.Impact of EBC analysis on mechanically
ventilated patients
Once a standardized method of performing EBC is estab-
lished, clinicians may be able to monitor specific disease
processes with a simple non-invasive study that can easily be
repeated, allowing for frequent reevaluation of a patient’s
condition. The patterns of change in exhaled volatile gases
seen in previous investigations illustrate this potential for
monitoring pulmonary conditions by analyzing breath
composition. Inflammatory biomarkers have been identified
and could serve as prognosticators of disease, guiding clinical
decision making. Increased effort focusing specifically on
identifying new biomarkers and associated reference values
will help to determine the best clinical application of EBC.
Invasive means of studying the lungs, such as BAL, are
associated with risks of interrupting ventilation and/or
causing injury and infection to the patient’s airway, com-
pounding the patient’s underlying condition. EBC avoids
iatrogenic inflammation or injury and does not interrupt the
recovery process of sick patients. Patients who have been
intubated secondary to respiratory failure are already
significantly ill and in some cases cannot tolerate even
simple bronchoscopy to obtain a BAL sample. EBC would be
useful in these patients because it has minimal effect on
the ventilator circuit and has been demonstrated to be safe
when performed continuously or short term with or without
humidification.2,3
Diseases examined by EBC in mechanically ventilated
patients include COPD,9 acute lung injury/acute respiratory
distress syndrome,9,11,13,16,18e20,22,23,29 pneumonia,11,15,16
as well as in healthy lungs of patients with concurrent
illness such as brain injury25 and elective thoracic surgery12
(Table 4). This represents a small fraction of the possible
disease states that could be examined using this method.
Many other conditions have been examined in volunteers in
Table 4 Disease processes examined with EBC during mechanical ventilation.
Disease Patient # Authors
Brain Injury 27 Korovesi I et al., 2011
Head Injury, Extra pulmonary
sepsis, Infection of CNS,
Burns
30 (4 Head Injury, 4 Extra
pulmonary sepsis, 1 Infection
of CNS, 1 Burns, 20 Healthy)
Roca O et al., 2010
ALI 6 Roca O et al., 2008
ALI, ARDS 40 (30 ALI/ARDS, 10 Control) Gessner C et al., 2007
VAP 23 (14 VAP, 9 Control) Horonenko G et al., 2007
Various: PNA, aspiration PNA,
persistent pulmonary
hypertension of the
newborn, sepsis-related
respiratory failure, tracheo-
esophageal fistula, CDH,
CLD, lung contusion,
bronchiolitis, pneumonitis,
asthma, head trauma
36 Humidification, 14 No
Humidification, 27 Control (12
PNA, 16 aspiration PNA, 6
persistent pulmonary
hypertension of the newborn, 4
sepsis-related respiratory
failure, 3 tracheo-esophageal
fistula, 1 CDH, 7 CLD, 3 lung
contusion, 5 bronchiolitis, 4
pneumonitis, 8 asthma, 6 head
trauma)
Mu¨ller WG et al., 2006
Multilobar PNA, COPD with
super infection, VAP
48 [14 Asymptomatic, 13
Multilobar PNA, 14 COPD with
super infection, 7 VAP]
Romero PV et al., 2006
ALI, ARDS, PNA 44 (11 ALI/ARDS/PNA, 12
Smoking, 21 Non-smoking)
Sack U et al., 2006
Various: Brain injury, reactive
airway disease, RSV s/p heart
transplant, PNA (CF), asthma
exacerbation, subglottic
stenosis, CDH, multiple
trauma, near drowning,
arteriovenous canal, lung
contusions,
bronchopulmonary dysplasia
with pulmonary
hypertension, liver failure,
failure of prosthetic valve
19 (2 Brain injury, 2 reactive
airway disease, 1 RSV s/p heart
transplant, 1 PNA (CF), 1
asthma exacerbation, 3
subglottic stenosis, 1 CDH, 2
multiple trauma, 1 near
drowning, 1 arteriovenous
canal, 1 lung contusions, 1
bronchopulmonary dysplasia
with pulmonary hypertension,
1 liver failure, 1 failure of
prosthetic valve)
Walsh BK et al., 2006
ARDS 6 Bruhn A et al., 2005
COPD 130 (11 COPD requiring
Mechanical Ventilation, 34
COPD exacerbation, 40 Stable
COPD, 21 Smoking, 24 Non-
smoking)
Gessner C et al., 2005
Elective Thoracic Surgery 45 (26 CABG, 19
Pneumonectomy)
Moloney ED et al., 2004
ARDS, ALI 35 (15 ARDS, 12 ALI, 8 Control) Gessner C et al., 2003
ALI, ARDS, PNA 35 (15 ARDS, 13 ALI, 7 Control) Gessner C et al., 2003
ARDS 14 Heard SO et al., 1999
ARDS, ALI 32 (22 ARDS/ALI, 10 Control) Carpenter CT et al., 1998
Ventilator dependent
(Unspecified)
34 Von Pohle WR et al., 1992
ARDS 68 (55 ARDS, 13 Control) Sznajder JI et al., 1989
ARDS 43 Baldwin SR et al., 1986
Disease: ALI - Acute Lung Injury, ARDS - Adult Respiratory Distress Syndrome, CABG e Coronary Artery Bypass Graft, CDH e Congenital
Diaphragmatic Hernia CF e Cystic Fibrosis, CLD e Chronic Lung Disease, CNS - Central Nervous System, COPD e Chronic Obstructive
Pulmonary Disease, PNA - Pneumonia, VAP - Ventilator associated pneumonia.
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a mechanically ventilated patient in more severe disease
states. There is currently limited literature examining the
inflammatory profile of mechanically ventilated trauma or
burn inhalation injury patients using this technique,
although these patients have been included in studies
looking at various aspects of EBC.2,3 The ultimate potential
of this technology is as a safe and efficient method for
identifying inflammatory profiles in disease states that
could help guide clinical decision making.Summary
Methods to incorporate EBC into a mechanical ventilator
circuit have been established, and studies describing this
technology have been available for thirty years. Collection
of EBC in mechanical ventilation follows basic principles of
condensation, but is influenced by multiple factors. These
factors need to be taken into consideration in order to
perform effective collection. The collection and analysis of
biomarkers needs to be tailored to specific compounds of
interest. Analysis of biomarkers in EBC requires proper
storage and choice of assay, with validation of previously
unused assays.
Of the described collection devices, R-Tube and
ECoScreen have been studied most extensively. While R-
Tube is easy to use and cheap, it is not specifically designed
for use in mechanical ventilation and must be adapted to fit
into the ventilator circuit. It is more affected by ambient
temperature as well. If the R-Tube could be redesigned for
use with mechanical ventilator tubing, this would facilitate
its use. ECoScreen and TURBO-DECCS devices are easily
incorporated into a mechanical ventilation circuit, but are
expensive and more cumbersome to transport, limiting their
use. Device size is a significant problem, especially if one has
to travel a distance to get from an ICU to a laboratory. The
ANACON device is not well documented in the literature,
making it difficult to comment on its utility at this time.
There remains too much variability in collection
methods and analysis of biomarkers and there is a lack of
normal reference values for mediators, preventing stan-
dardization. Standardization should be specific for indi-
vidual biomarkers, seeing as a more general model would
not optimize collection of all compounds. Collection of EBC
in the ambulatory population or in volunteers undergoing
mechanically ventilation for surgical procedures may serve
as controls for obtaining reference values. The first step in
standardization of EBC is appropriate documentation of
collection conditions and processing of EBC for specific
biomarkers in order to compare data between investiga-
tors. The ATS/ERS task force recommendations on EBC
should serve as a guide for investigators performing studies
with EBC. Through collaboration and comparison of tech-
niques and data collection, optimal methods for studying
EBC will be determined.
Adaptation of EBC to mechanical ventilators is seemingly
safe through continued use without reported major adverse
events. It has been applied to numerous pulmonary condi-
tions. EBC collection and analysis of biomarkers specific to
these disease processes has clinical implications in diagnosis,
therapeutics and prognostication. Sample collection inmechanically ventilated patients is completely non-invasive.
By comparing EBC to more invasive methods of pulmonary
monitoring, there is the potential to replace or substitute for
techniques that involve more risk to the patient. Avoiding
invasive procedures is of benefit to all patients, especially
those with greater acuity requiring mechanical ventilation.
Conclusion
The potential for EBC to function as a safe, non-invasive tool
for examining the severity of lung injury is tremendous. A
framework for performing EBC collection in mechanically
ventilated patients has been successfully documented, but
needs to be expanded to other diseases such as autoimmune
and connective tissue disorders, and inflammation secondary
to traumatic lung injury such as pulmonary contusions or burn
inhalation injury. Documentation of patient safety by moni-
toring vital signs and cardiac parameters during specimen
collection as well as for any adverse events will be important
in clinical acceptance of this procedure. The non-invasive
nature of EBC eliminates procedural risks that in some cases
are not tolerated by the critically ill. Once standardization is
established, EBC could serve as an alternative to more
invasive procedures such as bronchoscopy, bronchoalveolar
lavage and biopsy. In order to address issues of standardiza-
tion, comparative studies between collection devices and
techniques, modes and conditions of ventilation such as
humidifier use, and biomarker processing needs to be per-
formed. Standardization will need to be specific for each
individual biomarker with future investigations focusing on
optimal collection conditions.
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